(Q28342507)

Antimicrobial Agents and Chemotherapy

inferred from page(s)

published in

0 references

volume

33

0 references

page(s)

1-5

0 references

issue

1

0 references

cites work

In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Ability of ciprofloxacin but not pipemidic acid to differentiate all three biovariants of Mycobacterium fortuitum from Mycobacterium chelonae

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Drug interactions of ciprofloxacin with other non-antibiotic agents

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Ciprofloxacin: an overview of adverse experiences

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Comparative pharmacokinetic parameters of new systemic fluoroquinolones.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Tissue penetration of ciprofloxacin after single and multiple doses

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Ciprofloxacin concentrations in bone and muscle after oral dosing

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

In vitro antimycobacterial activity of a new antibacterial substance DL-8280--differentiation between some species of mycobacteria and related organisms by the DL-8280 susceptibility test

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280).

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Lung infections due to Mycobacterium fortuitum and Mycobacterium chelonae. Reports of nine cases of M. fortuitum infection and four cases of M. chelonae infection

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Overview of preclinical studies with ciprofloxacin

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Ciprofloxacin increases serum levels of theophylline

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Differentiation of Mycobacterium gordonae from Mycobacterium scrofulaceum and Mycobacterium szulgai by susceptibility to enoxacin (antimycobacterial activity of enoxacin).

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

[Comparison of in vitro growth-inhibitory activities of ofloxacin, ciprofloxacin and norfloxacin against various species of mycobacteria (comparison of organ concentrations and blood concentrations in mice)]

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

[Tissue concentration and effectiveness of ofloxacin in surgical patients].

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Activity of five fluoroquinolones against Mycobacterium avium-intracellulare complex and M. xenopi

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

In vitro activity of five new quinolones against cultivable mycobacteria

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Comparative in-vitro activity of five fluoroquinolones against mycobacteria

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Effect of Ro 23-6240 on sensitive and resistant intracellular mycobacteria.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

[Salvage treatment of multi-resistant pulmonary tuberculosis. Efficacy of pefloxacine].

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

[Differentiation between mycobacterial species by the susceptibility test to ciprofloxacin--comparison of antimycobacterial spectra between ofloxacin and ciprofloxacin]

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Differentiation of Mycobacterium chelonei from M. fortuitum by ciprofloxacin susceptibility

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

In vitro synergistic activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against Mycobacterium avium-intracellulare complex

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

In-vitro activity of some quinoline derivatives against Mycobacterium fortuitum.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

In vitro activity of the new quinoline derivative ciprofloxacin alone and in combination against various Mycobacterium-, Salmonella- and Escherichia coli strains.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

In-vitro susceptibility of mycobacteria to ciprofloxacin.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171410

Clinical, microbiological and pharmacokinetic studies on ofloxacin in acute purulent exacerbations of chronic respiratory disease

27 November 2018

1 reference

12 December 2020

In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae

1 reference

12 December 2020

Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum

1 reference

12 December 2020

In vitro activity of ciprofloxacin and ofloxacin against the Mycobacterium avium-intracellulare complex

1 reference

12 December 2020

In-vitro activity of fleroxacin (Ro 23-6240), a new fluoro-quinolone, and other agents, against Mycobacterium spp

1 reference

12 December 2020

Long-term results of medical treatment in Mycobacterium intracellulare infection

1 reference

12 December 2020

Treatment of disease due to Mycobacterium intracellulare

1 reference

12 December 2020

[Superoxide anion (O2-) release from mouse peritoneal macrophages associated with ingestion of mycobacteria and effects of O2- on intracellular multiplication of mycobacteria]

1 reference

12 December 2020

In vitro activity of ciprofloxacin against mycobacteria

1 reference

12 December 2020

Uptake of ciprofloxacin by human neutrophils

1 reference

12 December 2020

Antituberculosis activity of ofloxacin (DL 8280) on experimental tuberculosis in mice

1 reference

12 December 2020

In-vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs

1 reference

12 December 2020

Penetration of ciprofloxacin into gynecological tissues following oral and intravenous administration

1 reference

12 December 2020

[Clinical pharmacology of ofloxacin: a new chemotherapeutic agent belonging to the gyrase inhibitor group]

1 reference

12 December 2020

Pharmacokinetics of ofloxacin and theophylline alone and in combination

1 reference

12 December 2020

[New oral quinolone compounds in chronic bronchitis]

1 reference

12 December 2020

Mycobacterium fortuitum peritonitis associated with continuous ambulatory peritoneal dialysis

1 reference

12 December 2020

[Antituberculosis chemotherapy including ofloxacin in patients with pulmonary tuberculosis not treated previously]

1 reference

12 December 2020

The pharmacokinetics and tissue penetration of ofloxacin

1 reference

12 December 2020

Tissue distribution of ciprofloxacin following oral and intravenous administration

1 reference

12 December 2020

The comparative pharmacokinetics of five quinolones

1 reference

12 December 2020

New active drugs against the tuberculosis bacillus and other mycobacteria

1 reference

12 December 2020

In vitro and in vivo activities of ofloxacin against Mycobacterium leprae infection induced in mice

1 reference

12 December 2020

Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse

1 reference

12 December 2020

Tissue penetration and metabolism of ciprofloxacin

1 reference

12 December 2020